Drug Profile

BIIB 061

Alternative Names: BIIB-061

Latest Information Update: 15 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biogen Idec
Developer Biogen
Class Neuroprotectants; Small molecules
Mechanism of Action Myelin protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Multiple sclerosis

Most Recent Events

15 Jun 2023 Discontinued - Phase-I for Multiple sclerosis (In volunteers) in USA (PO) (Biogen pipeline, June 2023)
01 Jun 2023 Biogen withdraws a phase II trial prior to enrolment in Multiple sclerosis (Adjunctive treatment) (PO), due to lack of stronger preclinical effects on remyelination(NCT04079088)
13 Dec 2021 BIIB 061 is still in phase I trials for Multiple-sclerosis in USA (Biogen website, December 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com